Home
Storia in 3 fonti
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended rejection of AstraZeneca’s novel cancer drug, Europe’s CHMP has blessed Etcamah with a positive opinion. The EMA also has signed off on Novo Nordisk's Wegovy pill.
- ·
fiercepharma.com
Roche narrowly edges out AstraZeneca for the top-rated oncology MSL team: survey
Roche/Genentech and AstraZeneca have the best-performing medical science liaison (MSL) teams in oncology, according to a ZoomRx survey of physicians. | Roche/Genentech and…
- ·
Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. | Merck & Co. and Kelun-Biotech's sac-TMT is on fire…
- ·
statnews.com
EU and US advisers split over AstraZeneca breast cancer drug
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
- ·
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is…
- ·
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended rejection of AstraZeneca’s novel cancer drug, Europe’s…
- ·
endpoints.news
AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel
Europe's CHMP backed AstraZeneca's camizestrant for breast cancer, diverging from a recent FDA committee vote, as well as Novo Nordisk's Wegovy pill for obesity.